Kura Oncology logo

Kura Oncology Funding & Investors

Kura Oncology, Inc. operates as a clinical stage biopharmaceutical company. The Company focuses on discovery and development of personalized therapeutics for the treatment of tumors and blood cancers. Kura Oncology offers development programs for cancers with high unmet need, including lung, colorectal, thyroid, blood, and pancreatic cancers.

kuraoncology.com

Total Amount Raised: $1,241,425,536

Kura Oncology Funding Rounds

  • Post Ipo Equity

    $150,000,000

    Post Ipo Equity Investors

    Suvretta Capital Management
    EcoR1 Capital
    Deerfield Management
  • Post Ipo Equity

    $100,000,000

  • Post Ipo Debt

    $125,000,000

    Post Ipo Debt Investors

    Hercules Capital
  • Post Ipo Equity

    $25,000,000

    Post Ipo Equity Investors

    Bristol-Myers Squibb
  • Post Ipo Equity

    $345,080,500

  • Post Ipo Equity

    $143,900,000

  • Post Ipo Equity

    $115,345,000

  • Post Ipo Equity

    $77,050,000

  • Post Ipo Equity

    $50,050,000

  • Post Ipo Equity

    $50,000,000

  • Private Equity

    $60,000,000

    Private Equity Investors

    EcoR1 Capital
    Arch Venture Partners
    Nextech Invest
    Osage University Partners (OUP)
    Fidelity Investments
    Tavistock Group
    PFM Health Sciences
  • IPO

    Unknown

Funding info provided by Diffbot.